Ruiqiang Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruiqiang Lu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Huanxiang Liu
Macao Polytechnic University
1 shared publication - Shuoyan Tan
State Key Laboratory of Chinese Medicine Modernization Innovation Center of Yangtze River Delta, Zhejiang University Jiaxing China
1 shared publication - Xiaojun Yao
Macao Polytechnic University
1 shared publication - Zhenglu Chen
School of Pharmacy Lanzhou University Lanzhou 730000 China
1 shared publication
Latest Publications
- 24 March 2025
- Published by Wiley in WIREs Computational Molecular Science
- Vol. 15 (2)
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Proteolysis targeting chimera (PROTAC) induces specific protein degradation through the ubiquitin–proteasome system and offers significant advantages over small molecule drugs. They are emerging as a promising avenue, particularly in targeting previously “undruggable” targets. Traditional PROTACs have been discovered through large‐scale experimental screening. Extensive research efforts have been focused on unraveling the biological and pharmacological functions of PROTACs, with significant strides made toward transitioning from empirical discovery to rational, structure‐based design strategies. This review provides an overview of recent representative computer‐aided drug design studies focused on PROTACs. We highlight how the utilization of the targeted protein degradation database, molecular modeling techniques, machine learning algorithms, and computational methods contributes to facilitating PROTAC discovery. Furthermore, we conclude the achievements in the PROTAC field and explore challenges and future directions. We aim to offer insights and references for future computational studies and the rational design of PROTACs.
- 24 March 2025
- Published by Wiley in WIREs Computational Molecular Science
- Vol. 15 (2)
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Proteolysis targeting chimera (PROTAC) induces specific protein degradation through the ubiquitin–proteasome system and offers significant advantages over small molecule drugs. They are emerging as a promising avenue, particularly in targeting previously “undruggable” targets. Traditional PROTACs have been discovered through large‐scale experimental screening. Extensive research efforts have been focused on unraveling the biological and pharmacological functions of PROTACs, with significant strides made toward transitioning from empirical discovery to rational, structure‐based design strategies. This review provides an overview of recent representative computer‐aided drug design studies focused on PROTACs. We highlight how the utilization of the targeted protein degradation database, molecular modeling techniques, machine learning algorithms, and computational methods contributes to facilitating PROTAC discovery. Furthermore, we conclude the achievements in the PROTAC field and explore challenges and future directions. We aim to offer insights and references for future computational studies and the rational design of PROTACs.